EULAR: European Alliance of Associations for Rheumatology
Guidelines
Systemic JIA and AOSD are the same disease, EULAR says
New recommendations state that the ultimate goal of treatment should be drug-free remission.
Guidelines
EULAR issues imaging recommendations for crystal-induced arthropathies
The document provides guidance on using imaging in both the diagnosis and management of all common forms of crystal-induced arthropathies.
Conference Coverage
Latest data: COVID vaccine safety, protection, and breakthrough infections in inflammatory, autoimmune diseases
EULAR 2023 served up a bevy of studies on the protection and safety of COVID vaccines for patients and pregnant and breastfeeding women, as well...
Guidelines
New EULAR lupus recommendations advise using biologics, tapering steroids
The 2023 recommendations cover new treatment strategies with more ambitious goals, new data on adverse effects of chronic glucocorticoid use, and...
Conference Coverage
AI efforts make strides in predicting progression to RA
Two independent efforts to use artificial intelligence to predict the development of early RA from patients with signs and symptoms not meeting...
Conference Coverage
RA and demyelinating disease: No consistent link to TNFi
Patients with rheumatoid arthritis who take a tumor necrosis factor inhibitor do not appear to have a consistent and significant risk for...
Conference Coverage
High-intensity interval training has sustainable effects in patients with inflammatory arthritis
Patients in a randomized trial improved their cardiorespiratory fitness, but the positive response did not coincide with changes in pain or...
Conference Coverage
Dazodalibep may mitigate Sjögren’s syndrome, but more data are needed
The novel agent targets CD40 ligand and showed promising results in a two-stage, phase 2 clinical trial, particularly for patients with notable...
Guidelines
EULAR PsA recommendations update emphasizes safety, nonmusculoskeletal manifestations
The update builds on 2019 recommendations and incorporates safety concerns about JAK inhibitors, advises on differential drug efficacy across...
Conference Coverage
Long COVID risk not higher with rheumatic diseases
“The data demonstrate that rheumatic disease itself is not a risk factor for long COVID. However, patients with rheumatic diseases are at a higher...
Conference Coverage
Studies reveal nuances in efficacy, MACE risk between JAKi and TNFi
Three studies provide more data on risk for major adverse cardiovascular events with JAK inhibitors vs. TNF inhibitors, as well as their efficacy...
Conference Coverage
Early axial spondyloarthritis diagnosis in referred patients remains stable in most
Patients who are diagnosed with axial spondyloarthritis after referral to a rheumatologist for chronic back pain most often keep that diagnosis,...
Conference Coverage
Investigational uricase-based gout drug meets primary endpoints in phase 3 trials
Two phase 3 trials of the once-monthly SEL-212 in refractory gout achieved and maintained serum uric acid < 6 mg/dL for ≥ 80% of the final...
Conference Coverage
EULAR systemic sclerosis recommendations now include immunosuppressants
The update to 2017 recommendations include targeted synthetic and biologic DMARDs for the first time.
Conference Coverage
URAT1 inhibitor shows ‘substantial’ uric acid reduction in phase 2 gout trial
The investigational drug, AR882, reduced serum uric acid to levels seen in people without hyperuricemia and gout.